Refining the management of low-grade cervical abnormalities in the UK National Health Service and defining the potential for human papillomavirus testing: A commentary on emerging evidence

Journal of Lower Genital Tract Disease

Volumn 10, Issue 1, 2006, Pages 26-38

  Bentley, Elaine ^a   Cotton, Seonaidh C ^b   Cruickshank, Margaret E ^b   Duncan, Ian ^c   Gray, Nicola M ^b   Jenkins, David ^d   Little, Julian ^b,e   Neal, Keith ^a   Philips, Zoë ^f   Russell, Ian ^g   Seth, Rashmi ^h   Sharp, Linda ^b,i   Waugh, Norman ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d GSK   (Belgium)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g BANGOR UNIVERSITY   (United Kingdom)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

ⁱ NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

CANCER SCREENING; COLPOSCOPY; DISEASE SEVERITY; HUMAN; NOTE; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS LOAD; WART VIRUS; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PRACTICE GUIDELINE; PRECANCER; PREDICTION AND FORECASTING; PUBLIC HEALTH; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

COLPOSCOPY; FEMALE; GREAT BRITAIN; HUMANS; MASS SCREENING; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 33645642879     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.lgt.0000192695.93172.75     Document Type: Note

References (112)

1. NHS Scotland, Information & Statistics Division. Cervical cytology workload statistics (Quarter ending 31 March 2005). Available at: http://www.isdscotland.org/isd/info3.jsp?pcontentid=2887ampp_applic= cccampp_service=content.show (accessed 29 September 2005).
2. Patnick J (ed). Making a difference: NHS Cervical Screening Programme Annual Review 2004. Sheffield: NHS Cervical Screening Programme; 2004. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/2004review.html (accessed 29 September 2005).
3. Evans DMD, Hudson EA, Brown CL, Boddington MM, Hughes HE, MacKenzie EFD et al. Terminology in gynaecological cytopathology: report of the working party of the BSCC. J Clin Pathol 1986;39:933-44.
4. Johnson J, Patnick J (eds). Achievable standards, benchmarks for reporting and criteria for evaluating cervical cytopathology. NHCSP Publication No 1. Second edition. Sheffield: NHS Cancer Screening Programme; 2000. Available at: http://www.cancerscreening.nhs.uk/cervical/csp01.pdf (accessed 29 September 2005).
5. Kurman RJ, Solomon D. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. New York: Springer-Verlag; 1994:1-81.
6. Walker EM, Dodgson J, Duncan ID. Does mild atypia on a cervical smear warrant further investigation? Lancet 1986;2:672-3.
7. Johnson N, Sutton J, Thornton JG, Lilford RJ, Johnson VA, Peel KR. Decision analysis for best management of mildly dyskaryotic smear. Lancet 1993;342:91-6.
8. Johnson N, Sutton J, Thornton J, Lilford R, Johnson V, Peel R. Management of mildly dyskaryotic smears. Lancet 1993;342:813-4.
9. Soutter WP, Fletcher A. Invasive cancer of the cervix in women with mild dyskaryosis followed up cytologically. Br Med J 1994;308:1421-3.
10. Flannelly G, Kitchener H. Every woman with an abnormal cervical smear should be referred for treatment: debate. Clin Obstet Gynecol 1995;38:585-91.
11. Prendiville W, Walker P. Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Clin Obstet Gynecol 1995;38:592-9.
12. Shafi MI, Luesley DM. Management of low grade lesions: follow-up or treat? Baillieres Clin Obstet Gynaecol 1995;9:121-31.
13. Ifaturoti OO, Lockwood S, Etheridge M, Ong PS, Rashid F, Jones MH. An alternative approach to the management dilemma of the mildly dyskaryotic smear based on audit of outcome. Cytopathology 2000;11:268-74.
14. Lyall H, Duncan ID. Inaccuracy of cytologic diagnosis in high grade squamous intraepithelial lesions (CIN 3). Acta Cytolog 1995;39:50-4.
15. Shafi MI, Luesley DM, Jordan JA, Dunn JA, Rollason TP, Yates M. Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. Br J Obstet Gynaecol 1997;104:590-4.
16. Soutter WP, Wisdom S, Brough AK, Monaghan JM. Should patients with mild atypia in a cervical smear be referred for colposcopy? Br J Obstet Gynaecol 1986;93:70-4.
17. Flannelly G, Anderson D, Kitchener HC, Mann EMF, Campbell M, Fisher P. Management of women with mild and moderate cervical dyskaryosis. Br Med J 1994;308:1399-403.
18. Robertson JH, Woodend BE, Crozier EH, Hutchinson J. Risk of cervical cancer associated with mild dyskaryosis. Br Med J 1988;297:18-21.
19. Fletcher A, Metaxas N, Grubb C, Chamberlain J. Four and a half year follow up of women with dyskaryotic cervical smears. Br Med J 1990;301:641-4.
20. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
21. International Agency for Research on Cancer. Cervix Cancer Screening: IARC Handbooks of Cancer Prevention, Vol. 10. Lyon: IARC Press; 2005:1-302.
22. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3(14):1-196.
23. NHS Cervical Screening Programmes. Colposcopy and Programme Management Guidelines for the NHS Cervical Screening Programme. NHSCSP Publication No 20. Sheffield: NHS Cervical Screening Programmes; 2004. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf (accessed 29 September 2005).
24. Raffle AE. Cervical screening. Br Med J 2004;328:1272-3.
25. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
26. Melnikow J, Nuovo J, Willan AR, Chan BKS, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
27. Schiffman M, Adrianza ME. ASCUS-LSIL triage study. Design, methods and characteristics of trial participants. Acta Cytolog 2000;44:726-42.
28. ALTS Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
29. ALTS Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400.
30. Sherman ME, Wang SS, Tarone R, Rich L, Schiffman M. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev 2003;12:372-9.
31. Moscicki A, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-83.
32. Kitchener HC, Burns S, Nelson L, Myers AJ, Fletcher I, Desai M. A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. BJOG 2004;111:63-70.
33. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996;89:257-60.
34. Ferris DG, Kriegel D, Cote L, Litaker M, Woodward L. Women's triage and management preferences for cervical cytologic reports demonstrating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions. Arch Fam Med 1997;6:348-53.
35. Melnikow J, Kuppermann M, Birch S, Chan BKS, Nuovo J. Management of the low-grade abnormal pap smear: what are women's preferences? J Fam Pract 2002;51:849-55.
36. Cecchini S, Iossa A, Bonardi R, Ciatto S, Cariaggi P. Comparing two modalities of management of women with cytologic evidence of squamous or glandular atypia: early repeat cytology or colposcopy. Tumori 1997;83:732-4.
37. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-10.
38. Flannelly G, Campbell MK, Meldrum P, Torgerson DJ, Templeton A, Kitchener HC. Immediate colposcopy or cytological surveillance for women with mild dyskaryosis: a cost effectiveness analysis. J Public Health Med 1997;19:419-23.
39. Sharp L. How should women with an abnormal smear be followed-up? Scottish Cancer Therapy Network Newsletter 2002;35:15-7. Available at: http://www.isdscotland.org/isd/files/sctn_news_35.pdf (accessed 29 September 2005).
40. Etherington IJ, Luesley DM, Shafi MI, Dunn J, Hiller L, Jordan JA. Observer variability among colposcopists from the West Midlands region. Br J Obstet Gynaecol 1997;104:1380-4.
41. Cardenas-Turanzas M, Follen M, Benedet J, Cantor SB. See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions. Lancet Oncol 2005;6:43-50.
42. Dunn TS, Killoran K, Wolf D. Complications of Outpatient LLETZ Procedures. J Reprod Med 2004;49:76-8.
43. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for Cervical Intraepithelial Neoplasia and Risk of Preterm Delivery. JAMA 2004;291:2100-6.
44. Tan L, Pepra E, Haloob RK. The outcome of pregnancy after large loop excision of the transformation zone of the cervix. J Obstet Gynaecol 2004;24:25-7.
45. Samson SA, Bentley JR, Fahey TJ, McKay DJ, Gill GH. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 2005;105:325-32.
46. Cinel A, Oselladore M, Insacco E, Minucci D. The accuracy of colposcopically directed biopsy in the diagnosis of cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 1990;11:433-7.
47. McCord ML, Stovall TG, Summitt RL Jr., Ling FW. Discrepancy of cervical cytology and colposcopic biopsy: is cervical conization necessary? Obstet Gynecol 1991;77:715-9.
48. Parham DM, Wiredu EK, Hussein KA. The cytological prediction of cervical intraepithelial neoplasia in colposcopically directed biopsies. Cytopathology 1991;2:285-90.
49. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Path 1993;12:186-2.
50. Kierkegaard O, Byrjalsen C, Frandsen KH, Hansen KC, Frydenberg M. Diagnostic accuracy of cytology and colposcopy in cervical squamous intraepithelial lesions. Acta Obstet Gynecol Scand 1994;73:648-51.
51. Baldauf JJ, Dreyfus M, Ritter J, Philippe E. An analysis of the factors involved in the diagnostic accuracy of colposcopically directed biopsy. Acta Obstet Gynecol Scand 1997;76:468-73.
52. Heatley MK, Bury JP. The correlation between the grade of dyskaryosis on cervical smear, grade of cervical intraepithelial neoplasia (CIN) on punch biopsy and the final histological diagnosis on cone biopsies of the cervix. Cytopathology 1998;9:93-9.
53. Brink AATP, Zielinski GD, Steenbergen RDM, Snijders PJF, Meijer CJLM. Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology 2005;16:7-12.
54. Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
55. Nobbenhuis MAE, Meijer CJLM, Van Den Brule AJC, Rozendaal L, Voorhorst FJ, Risse EKJ. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
56. Koutsky L, Kiviat NB. Genital human papillomavirus In: Holmes KK, Mardh PA, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserheit JN (eds). Sexually Transmitted Diseases, Third edition. New York: McGraw-Hill; 1999:347-59.
57. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
58. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities. Arch Pathol Lab Med 2003;127:1169-75.
59. Solomon D, Schiffman M. Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst 2004;96:250-1.
60. Office for National Statistics. Sexual partners: averages up. Available at: http://www.statistics.gov.uk/cci/nugget.asp?id=411 (accessed 29 September 2005).
61. Office for National Statistics. Sexual Health: Chlamydia Rates Continue to Rise. Available at: http://www.statistics.gov.uk/cci/nugget.asp?id=412 (accessed 29 September 2005).
62. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
63. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dilner J. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
64. Arbyn M, Buntinx F, Van Ranst M. Triage of Women with Atypical or Low-grade Cytological Abnormalities of the Cervix by HPV Testing: Systematic Review and Meta-analysis. PH/EPI Reports Nr 2001-019[D/2001/2505/34]. Brussels: Scientific Institute of Public Health; 2002.
65. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A. A study of the impact of adding HPV types to cervical cancer screening and triage test. J Natl Cancer Inst 2005;97:147-50.
66. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367-72.
67. NHS Scotland. Cancer in Scotland: Action for Change. Annual Report 2003. Available at: http://www.scotland.gov.uk/publications/2003/10/18333/27774 (accessed 29 September 2005).
68. National Institute for Clinical Excellence. Guidance on the Use of Liquid-Based Cytology for Cervical Screening. Technology Appraisal 69. London: National Health Service; 2003. Available at: http://www.nice.org.uk/pdf/ ta69_lbc_review_fullguidance.pdf (accessed 29 September 2005).
69. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12:1038-44.
70. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103:519-24.
71. Snijders PJF, van den Brule AJC, Meijer CJLM. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
72. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-7.
73. Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:477-84.
74. Howard M, Sellors J, Kaczorowski J. Optimizing the hybrid capture II papillomavirus test to detect cervical intraepithelial neoplasia. Obstet Gynecol 2002;100:972-80.
75. Rozendaal L, Walboomers JMM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJM. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
76. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
77. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-84.
78. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
79. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000;183:561-7.
80. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PKE, Andersen PK, Pont NJ. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
81. Zielinski GD, Snijders PJF, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP. HPV presence precedes abnormal cytology in women developing cervical cancer and signals negative smears. Br J Cancer 2001;85:398-404.
82. Schlecht NF, Platt RW, Negassa A, Duarte-Franco E, Rohan TE, Villa LL. Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. Am J Epidemiol 2003;158:878-86.
83. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JCM. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.
84. Kjaer SK, Van Den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br Med J 2002;325:572-6.
85. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E. Risks for incident human papillomavirus infection and low grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
86. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. New Engl J Med 1999;341:1633-8.
87. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New Engl J Med 1992;327:1272-8.
88. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.
89. Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Verheijen RH. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005;116:122-9.
90. Philips Z, Johnson S, Avis M, Whynes DK. Human papillomavirus and the value of screening: young women's knowledge of cervical cancer. Health Educ Res 2003;18:318-28.
91. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res 2002;17:706-14.
92. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J. Awareness of human papillomavirus among women attending awellwoman clinic. Sex Transm Infect 2003;79:320-2.
93. Waller J, McCaffery K, Wardle J. Beliefs about the risk factors for cervical cancer in a British population sample. Prev Med 2004;38:745-53.
94. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003;88:42-6.
95. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. Br Med J 2004;328:1293-300.
96. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Can 2005;92:990-4.
97. Moss SM, Gray A, Marteau T, Legood R, Henstock E, Maissi E. Evaluation of HPV/LBC Cervical Screening Pilot Studies: Summary of Report to the Department of Health (Revised October 2004). NHS CSP; 2004. Available at: http://www.cancerscreening.nhs.uk/cervical/evaluation-hpv.pdf (accessed 29 September 2005).
98. Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004;91:84-91.
99. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-95.
100. Medical Sciences Advisory Committee. Human Papillomavirus Testing in Women with Cytological Prediction of Low-grade Abnormality. MSAC Reference 12b. Canberra: Medical Sciences Advisory Committee; 2003. Available at: http://www.msac.gov.au/pdfs/summary/summaryref12b.pdf (accessed 29 September 2005).
101. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
102. Cotton SC, Seth R, Sharp L, Grampian TOMBOLA Team, Nottingham TOMBOLA Team, Tayside TOMBOLA Team. Human papillomavirus infection in women with low-grade abnormal smear results in the UK. Joint Meeting of the International Epidemiological Association and Society for Social Medicine. Oxford, October 2001.
103. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:68-72.
104. Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia and the United Kingdom. Cancer 2002;96:14-20.
105. Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. Br Med J 2001;322:893-4.
106. Manos MM. HPV testing for clarifying borderline cervical smear results. Br Med J 2001;322:878-9.
107. Health Technology Assessment Programme. ARTISTIC Trial Project Data. Available at: http://www.hta.nhsweb.nhs.uk/projectdata/ 1_project_record_notpublished.asp?pjtid=1162ampsearchtext= you+selected++and++and+ (accessed 29 September 2005).
108. NHS Cervical Screening Programmes. ARTISTIC Trial. Available at: http://www.cancerscreening.nhs.uk/cervical/hpv.html#artistic-trial (accessed 29 September 2005).
109. Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ. Pobascam, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
110. Canadian Cervical Cancer Screening Trial. About the CCCaST Study. Available ay: http://www.mcgill.ca/cccast/ (accessed 29 September 2005).
111. Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
112. Monk BJ, Brewster WR. Does the ALTS trial apply to the community-based practitioner? Am J Obstet Gynecol 2003;188:1381-2.